Catalyst
Slingshot members are tracking this event:
Novartis' (NVS) FDA Priority Review Expected By May 14th for Midostaurin (PKC412) in Treatment of Acute Myeloid Leukemia (AML) in Newly-Diagnosed Adults with an FMS-Like Tyrosine Kinase-3 (FLT3) Mutation
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NVS |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 28, 2017
Occurred Source:
https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-rydaptr-newly-diagnosed-flt3-mutated-acute
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Fda, Priority Review, Midostaurin, Pkc412, Acute Myeloid Leukemia, Flt3 Mutation
